Crism Therapeutics (LSE:CRTX) Cash Flow for Dividends: £0.00 Mil (TTM As of Dec. 2025)


LSE:CRTX Crism Therapeutics Corp LSE:CRTX
37 GF Score
Price £0.10
! 3 Warning Signs
View Full Analysis

What is Crism Therapeutics Cash Flow for Dividends?

Crism Therapeutics LSE:CRTX 37 Cash Flow for Dividends is £0.00 Mil as of Dec. 2025. GuruFocus rates LSE:CRTX with a GF Score™ of 37/100. The stock has 3 warning signs investors should review.

Crism Therapeutics's cash flow for dividends for the six months ended in Dec. 2025 was £0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2025 was £0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Crism Therapeutics's annual payment of dividends declined from Dec. 2023 (£-24.69 Mil) to Dec. 2024 (£-0.05 Mil) and declined from Dec. 2024 (£-0.05 Mil) to Dec. 2025 (£0.00 Mil).

Crism Therapeutics Cash Flow for Dividends Related Terms

Crism Therapeutics Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Crism Therapeutics's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crism Therapeutics Cash Flow for Dividends Chart

Crism Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -24.69 -0.05 0.00

Crism Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LSE:CRTX
37GF Score
Crism Therapeutics Corp LSE:CRTX
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crism Therapeutics Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of £0.00 Mil mean?
Crism Therapeutics (LSE:CRTX) has a Cash Flow for Dividends of £0.00 Mil as of Dec. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Crism Therapeutics and its competitors.
Is Crism Therapeutics' Cash Flow for Dividends too high?
Crism Therapeutics' current Cash Flow for Dividends is £0.00 Mil. Overall, Crism Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Crism Therapeutics' Cash Flow for Dividends compare to VRTX and REGN?
Crism Therapeutics' Cash Flow for Dividends of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Crism Therapeutics and its competitors. Crism Therapeutics's current Cash Flow for Dividends is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crism Therapeutics stock overvalued right now?
Crism Therapeutics (LSE:CRTX) has a current Cash Flow for Dividends of £0.00 Mil. The current Cash Flow for Dividends is £0.00 Mil. Crism Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Crism Therapeutics (LSE:CRTX), the current Cash Flow for Dividends is £0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crism Therapeutics Business Description

Address Kingston Chambers, P.O. Box 173, Tortola, Road Town, VGB
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.
37GF Score

Get the complete analysis for LSE:CRTX

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.10
Price